PUBLIC COMPANY
save$URGNUroGen Pharma Ltd.
$URGN46.80-6.94%Ra'anana, ILupdated 15h ago
community read0 votes
pipeline
4
marketed
2
phase 3
2
catalysts ytd
1
approvals ytd
0
recalls ytd
0
Pipeline(4)
pipeline depth4 products
2Phase 32Marketed
Upcoming
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase3A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer
- phase3A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer
- phase1A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)
- —Named Patient Program for Mitomycin for Pyelocalyceal Solution
- —uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto
- phase3A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
- phase3Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC)
- phase3A Phase 3 Study of UGN-102 for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
🐶 Hiring Signal
next earnings Nov 5, 2026
News
no news has mentioned this company yet
Data sources
last refreshed 6m ago
Found something off?
comments(0)
5-min edit window · permanent after that